SCHEMBL23242520

SCHEMBL23242520

O=C(O)c1ccc(S)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 2/20 0.45
RARA P10276 1/20 0.45
RARG P13631 1/20 0.45
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
CYP1A2 P05177 1/20 0.42
EPHX2 P34913 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
ALB P02768 1/20 0.41
TRPV4 Q9HBA0 1/20 0.41
RXRA P19793 3/20 0.40
MAPT P10636 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
KEAP1 Q14145 2/20 0.39
KLKB1 P03952 1/20 0.39
CTSB P07858 1/20 0.39
MMP9 P14780 1/20 0.39
DNMT1 P26358 1/20 0.39
DNMT3B Q9UBC3 1/20 0.39
DNMT3L Q9UJW3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23699504 0.83 CES2 (0.43) CES2CES1CYP1A2ALBMAPT
SCHEMBL24452130 0.81 MAOB (0.49) CES2CES1TRPV4ALDH1A1
SCHEMBL1431441 0.79 ALDH1A1 (0.48) CYP1A2MAPTHDAC8ALDH1A1CA12
SCHEMBL9856029 0.79 FOLH1 (0.54) RARBRARARARGEPHX2NR1H4
SCHEMBL27793256 0.77 ALDH1A1 (0.46) CYP1A2MAPTHDAC8ALDH1A1CA12
SCHEMBL366061 0.77 CES2 (0.71) CES2CES1CYP1A2ALBMAPT
SCHEMBL16534058 0.77 RARB (0.60) RARBRARARARGCES2CES1
SCHEMBL30641680 0.77 RARB (0.60) RARBRARARARGCES2CES1
SCHEMBL542783 0.77 PRKAB2 (0.49) RARBRARARARGCES2CES1
SCHEMBL20178591 0.76 CA12 (0.46) TRPV4MAPTALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP claimed
CN-105801789-B A kind of aqueous polyurethane and preparation method thereof and adhesive 中国科学院长春应用化学研究所 2018-10-16 CN claimed
CN-106909027-A Photosensitive composition, colour filter and its preparation method, image display device 东友精细化工有限公司 2017-06-30 CN claimed
US-12245446-B2 Semiconductor device having quantum dots, display device, imaging system, and moving body CANON KABUSHIKI KAISHA (JP) 2025-03-04 US disclosed
CN-114929688-B 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders 阿莱瑞恩公司 2024-11-01 CN disclosed
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP disclosed
EP-4048667-B1 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANOIC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS ALAIRION INC (US) 2024-07-03 EP disclosed
EP-4048667-A1 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS Alairion, Inc. (US) 2022-08-31 EP disclosed
CN-114929688-A 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders 阿莱瑞恩公司 2022-08-19 CN disclosed
US-20220162253-A1 CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2022-05-26 US disclosed
CN-113285024-A Semiconductor device having quantum dots, display device, imaging system, and moving object 佳能株式会社 2021-08-20 CN disclosed
US-20210242416-A1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS, DISPLAY DEVICE, IMAGING SYSTEM, AND MOVING BODY CANON KABUSHIKI KAISHA (JP) 2021-08-05 US disclosed
EP-3859804-A2 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KABUSHIKI KAISHA (JP) 2021-08-04 EP disclosed
US-11046651-B2 Piperazine substituted azapine derivatives and uses thereof ALAIRION, INC. (US) 2021-06-29 US disclosed
WO-2021080997-A1 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS ALAIRION, INC. (US) 2021-04-29 WO disclosed
US-20210114989-A1 PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF Neumora Therapeutics, Inc. 2021-04-22 US disclosed
CN-109111405-A A kind of Aromatic Sulfide class compound and its pesticide and medical usage 南开大学 2019-01-01 CN disclosed
CN-105801789-B A kind of aqueous polyurethane and preparation method thereof and adhesive 中国科学院长春应用化学研究所 2018-10-16 CN disclosed
CN-106909027-A Photosensitive composition, colour filter and its preparation method, image display device 东友精细化工有限公司 2017-06-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046651-B2 Piperazine substituted azapine derivatives and uses thereof HTR2A, HTR5A, HTR2C RARB 1486/4885RARA 2088/4885RARG 1589/4885
US-20220162253-A1 CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ENTPD5, ENTPD1, NT5E RARB 3328/4885RARA 3267/4885RARG 3322/4885
US-20210114989-A1 PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF HTR2A, HTR5A, HTR2C RARB 1486/4885RARA 2088/4885RARG 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.